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Abstract This study was carried out with the aim of demonstrating the efficacy and tolerability of beclomethasone
dipropionate (BDP) aerosolspray 500mgb.i.d. via a spacerdevice (Jets,Chiesi Farmaceutici S.p.A.) usinganewHFA-134a
formulation or chlorofluorocarbon (CFC) propellant. After having completed a 2-week run-in period,154 adult patients
(77 in each group) with mild-to-moderate persistent asthma were randomised into two groups to receive the study
treatment for a duration of 12 weeks in a double-blind, multinational, multicentre, parallel-group design.Morning and
evening peak expiratory flow rate (PEFR), use of rescue salbutamol, number of day- and night--time asthma attacks,
number of night-time awakenings due to asthma and clinical symptomswere recorded daily by patients on diary cards.
Pulmonary function tests (FEV1, FVC, PEFR, FEF25--75%,MEF50 and FEF25) and vital signs were measured at the clinic at
studyentry, atthe startof treatment and every 2 weeks thereafter.Morning serumcortisol (8.00--10.00 a.m.) wasmea-
sured at the start and at the end of the treatment period. Adverse events were recorded throughout the total study
period. Significant improvements over baseline were reported in both groups in terms of lung function, symptoms and
use of rescue inhaled salbutamol. Equivalence between groups was demonstrated for the primary end-point morning
PEFR, as well as for evening PEFR and FEV1.No statistically significant differences in the comparisons between groups,
exceptfor FEF25 (P=0.044), wereobservedin anyofthe otherefficacy variables.Adverse eventswerereportedin 31% of
patients in the BDP--HFAgroup and in 32% in the CFC group. Adverse drug reactionswere 4 and 2 in the two groups,
respectively.No drug-related serious adverse eventswere reported in eitherof the groups.
No signsofrelevant adrenal suppressionwereobservedinbothgroups:2 patientsin eachgrouphad finalvaluesbelow
the normal range. In conclusion, the BDP--HFA-134a formulation proved to be equivalent in efficacy and comparable in
safety to the standard BDP--CFC product over 12 weeks in adult patients with mild-to-moderate persistent asthma.
r 2002 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2002.1348, available online at http://www.idealibrary.comon
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Chloro£uorocarbons (CFCs) have been used as propel-
lants in pressurized metered dose inhalers (pMDIs) in
the last four decades, and their delivery of a number of
treatments for asthma and chronic obstructive pulmon-
ary disease (COPD) has been proved as inexpensive,
reliable and e¡ective. However, due to their deleterious
e¡ects on the ozone layer (1), the Montreal protocol
(2) called for a phasing-out of the production of mostReceived 26 October 2001, accepted in revised form19 February 2002.
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Department Chiesi Farmaceutici, via Palermo 26/A, Parma, Italy.
Fax: +39 0521271992; E-mail: l.cantini@chiesigroup.comozone-damaging substances, including CFCs, and a great
challenge has been posed to pharmaceutical companies
in the reformulation of MDIs-products into CFC-
free forms. A number of drug substances, including in-
haled corticosteroids, b2-receptor agonists and anticho-
linergics, has been developed with the use of the
hydro£uoroalkane (HFA) 134a, a propellant de¢ned as
adequate for the use in pMDI-deliveredproducts (3). Be-
clomethasone dipropionate (BDP) was the ¢rst available
inhaled corticosteroid delivered with the HFA-134a.
Based on the evidence that the reformulation process
may modify the particle size distribution, and hence the
lung-deposition, the earliest extra¢ne HFA-134a-con-
taining BDP is marketed at a reduced recommended
ANEWHFA-134a PROPELLANTRESPIRATORYMEDICINE 785posology, compared with that of CFC-product (4). A
new HFA-134a formulation has been recently developed
by Chiesi Farmaceutici S.p.A. (Parma, Italy) with the in-
clusion of glycerol as non-volatile co-solvent, in order to
render the particle size of the inhaled drug as close as
possible to that of the conventional CFC (5). It has also
been noted that the selection of an appropriate actuator
ori¢ce diameter contributes to modulate an aerosol
cloud which can allow the maintenance of the 1:1
ratio between the doses of HFA and CFC-formulated
drugs (5).
The aim of the present study was to assess if BDP ad-
ministered with this newly developed HFA product is
equivalent, in terms of both e⁄cacy and safety, with the
conventional BDP--CFC, both drugsbeing givenwith the
addition of the Jets (Chiesi Farmaceutici S.p.A., Parma,
Italy) spacer.
PATIENTSANDMETHODS
Study population
Adult asthmatic patients were selected in eight centres,
located in Czech Republic and Poland, in an ambulatory
setting from patients attending the out-patients hospital
clinics.
Eligible patients had to satisfy the following criteria:
age between 18 and 70 years, mild-to-moderate
persistent asthma as de¢ned in standard guidelines (6),
forced expiratory volume in one sFFEV1Fbetween
60 and 90% of the predicted normal value, reversibility
to b2-agonists in the recent history and a satisfactory
degree of co-operation. Subjects with evidence of asth-
ma exacerbation or respiratory tract infections in the
previous 4 weeks, clinically signi¢cant diseases whose
treatment and sequelae could have interfered with the
result of the study, intake of oral corticosteroids in the
previous 8 weeks or inhaled corticosteroids at a daily
dose exceeding 1000mg of equivalent BDP, diagnosis of
chronic obstructive pulmonary disease (COPD) and/or
heavy smokers, pregnancy or at risk of pregnancy, inabil-
ity to complete the diary cards and hypersensitivity to
inhaled corticosteroids were excluded from participat-
ing in the study. Subjects whose FEV1 increased 10% at
the end of the run-inwith respect to thevaluemeasured
at study entry were also excluded from the treatment
phase.
Among the antiasthma treatments, inhaled corticos-
teroids (when taken at study entry) were permitted dur-
ing the run-in, sodium cromoglycate or nedocromil
sodium (when taken at study entry) were permitted at a
constant dose throughout recorded in a diary card. Pa-
tients were withdrawn from the study when any of the
following treatment was taken: theophyllines, anticholi-
nergics, antihistamines, leukotriene receptor antago-nists, oral corticosteroids, inhaled long-acting b2-
agonist and oral bronchodilators.
Study design andprotocol
This was a multicentre, randomised, double-blind, paral-
lel-group trial. Eligible patients entered a 2-week run-in
period and were then randomised to receive inhaled
BDP delivered with the HFA or the CFC (Clenil Forte
JETs, Chiesi farmaceutici S.p.A., Italy) propellant, both
drugs given at a dose of 2 pu¡s (250mg 2) twice daily,
morning and evening.The two treatment tests were ad-
ministeredwith a spacer device ( Jets,Chiesi Farmaceu-
tici S.p.A., Italy) at a constant dose (1mg/day), over a12-
week treatment duration.
Visits at the clinics took place every 2 weeks.On each
visit, the following pulmonary function tests were mea-
sured: FEV1 (L), forced vital capacity (FVC, L), peak ex-
piratory £ow rate (PEFR, L/s), mid-expiratory £ow at
50%vital capacity (MEF50,L/s) and forcedexpiratory £ow
at 25 and 75% FVC (FEF25--75% L/s).Three tests were per-
formed on each session and the best (that with the high-
est FEV1) was recorded. If inhaled salbutamolwas used, a
minimum of 6h had to elapse between inhalation and
pulmonary function measurements. Measuring condi-
tions, equipment and daily calibration of the instrument
were standardised as recommendedby theGuidelines of
the European Respiratory Society (7). A daily self-mea-
surementof PEFR (L/min)was alsoperformed twicedaily
(morning and evening) using a portable peak £owmeter
(Mini-Wrights, Airmed,Clement Clarke,U.K.); the best
of three consecutive £ows had to be recorded. In addi-
tion, the intake of rescue salbutamol (number of pu¡s/
day)wasrecordeddailybypatients in a diarycard, aswell
as the number of day- and nighttime asthma attacks and
the number of nighttime awakenings caused by asthma.
Clinical symptoms (dyspnoea, tachypnoea, wheezing,
cough and catarrh) were also measured daily using a 4-
point rating scale (where 0=none; 1=slight and transi-
ent; 2=moderate; and 3=severe) to obtain a global sum
of scores.
Ablood samplewas taken from an antecubital veinbe-
tween 08.00 and10.00 a.m. at the start and at the end of
treatment for themeasurementofmorning serumcorti-
sol; assessment was done in a centralised laboratory
using a solid-phase, chemiluminescent enzyme immu-
noassay.
Pulse and blood pressureweremeasured at each visit.
Patients reported adverse events at each visit and
their severity, outcome and correlation with the study
treatments were assessed.
Compliance was evaluated by recording the daily
doses of the administered drug into a diary card and by
inspecting the used and unused returned canisters at
each visit.The proportion of the administered drug was
TABLE 1. Baseline characteristicsofthepatients’popula-
tion
BDP--HFA
(n=77)
BDP--CFC
(n=77)
Sex:
Males (n) 39 (51%) 43 (56%)
Females (n) 38 (49%) 34 (44%)
Age, years (mean7SD) 38.0712.1 37.4713.3
Height, cm (mean7SD) 171.479.3 172.679.5
Weight, kg (mean7SD) 73.5714.7 75.8712.6
Duration of asthma, years
(mean7SD)
9.779.3 9.378.0
Morning PEFR,L/min
(mean7SD)
416.7795.2 413.7784.2
Evening PEFR,L/min
(mean7SD)
427.2791.5 428.5786.2
FEV1predicted, % (mean7SD) 77.277.9 76.879.0
786 RESPIRATORYMEDICINEthen calculated: the limit for a satisfactory compliance
was set at 75%.
Ethics
The study protocol, patient information lea£et and in-
formed consent form were reviewed and approved by
the Independent Ethics Committees of each participat-
ing centre prior to the start of the study.
Statistics
The primary outcome variable was the morning peak
£ow.Based on the following assumptions: meanmorning
PEFR ¢nal value (last 2-week period) of 460L/min and
standard deviation (SD) of 90L/min in the CFC group;
power equal to 80% and level of signi¢cance equal to
5%; the sample size was determined to be 50 patients
per group.Equivalencewas proven if the 95% con¢dence
interval (CI) for the di¡erence between treatment
means fell within the range of710% of the adjusted
mean of the BDP CFC group (8).
Adjusted least-squaresmeans (LSMs) of the two treat-
ments were derived from an ANCOVA model using
baseline values as covariate. The 95% CI for the di¡er-
ence between LSMs was used to assess equivalence be-
tween the two treatments for morning and evening
PEFR, and FEV1, whereas the other PF tests, salbutamol
daily use, asthma attacks, clinical symptoms, morning
serum cortisol and vital signs were analysed by calculat-
ing the 95% CI for the mean change from baseline: data
were compared between groups using ANCOVA.
The baseline datawas that derived from themean va-
lues of the 2-week run-in period recorded on the dairy
cards and the data measured at the 2nd clinic visit. Two
weekly means were also calculated for the variables re-
corded in the dairy cards.
All randomised patients with post-baseline data were
included in the intent-to-treat (ITT) analysis andpatients
withmajor protocol violationswere to be excluded from
the per-protocol (PP) population. The last observation
carried forward (LOCF) method was used to deal with
themissing data.
RESULTS
A total of154 patients were randomised to receive study
medication, 77 in either of the group.Four patients, all in
the BDP--CFC group, were withdrawn from the study:
two of them did not satisfy the inclusion criteria (noted
throughout the study), one withdrew the consent and
another had adverse events (upper respiratory tract in-
fection). Only one of them did not have post-baseline
data and was excluded from the ITT population. Since
nomajor protocol violation occurred, the samepatients’
population entered the PP and the ITTanalysis.Most of patients were taking inhaled corticosteroids
at study entry and during run-in at a daily dose equal or
less than1mg: 43 (78.2%) patients in theHFA-134a group
and 38 (77.6%) in the CFC group were taking BDP,
whereas the remaining took budesonide, 11 (20.0%) in
the HFA-134a group and10 (20.4%) in the CFC group, or
£unisolide,1 (1.8%) in theHFA-134a group, and1 (2.0%) in
the CFC group.
The individual patient demographic details are pre-
sented inTable 1. The two groups were well matched in
respect of demographics and other baseline characteris-
tics, including the duration and severity (FEV1% pre-
dicted) of asthma.
The results of the primary outcome variable mean
morning PEFR and of evening PEFR, recordeddailybypa-
tients, are presented in Fig.1. Both variables signi¢cantly
increased over baseline at any 2-week period.
Morning PEFR (mean7SD) increased from
416.7795.2L/min (baseline) to 438.6795.0 L/min (¢nal)
in the BDP--HFA group, and from 413.7784.2 to
431.0788.1L/min in the BDP--CFC group. Evening PEFR
increased from 427.2791.5 to 447.4793.7 L/min in the
BDP--HFA group and from 428.5786.2 to 442.37
91.2 L/min in the BDP--CFC group.
The LSMs for morning PEFR were 437.7L/min for
BDP--HFA-134a and 431.7 L/min for BDP--CFC, with a dif-
ference of6.05L/min. Statistical analysis demonstrated
that BDP--HFA-134a was equivalent to BDP--CFC: bilat-
eral 95% CI for the treatment di¡erencewas19.7--7.6 L/
min, well within the equivalence limit of743.17L/min.
As regards to evening PEFR, the LSMs were 448.1L/
min for BDP--HFA-134a and 441.2L/min for BDP--CFC,
with a di¡erence of6.95L/min.The bilateral 95% CI for
the treatment di¡erence was 20.8--6.9 L/min, within
the equivalence limit of744.12L/min.
ANEWHFA-134a PROPELLANTRESPIRATORYMEDICINE 787Results of the other pulmonary function tests, mea-
sured at clinic visits, are shown in Table 2: FEV1, FVC,
PEFR, FEF25--75% andMEF50 markedly increased through-
out the study period in both groups.No statistically sig-FIG. 1. PEFR (l/min) measured daily expressed as twoWeekly
means (SDinbars).
TABLE 2. Pulmonary functiontests (95% CIof changes fromba
Treatment Baseline
(mean7SD)
FEV1(L) BDP--HFA 2.7370.66
BDP--CFC 2.7570.71
FVC(L) BDP--HFA 3.6270.93
BDP--CFC 3.8271.11
PEFR (L/s) BDP--HFA 6.3771.83
BDP--CFC 6.2571.79
FEF25--75% (L/sec) BDP--HFA 2.5471.05
BDP--CFC 2.3470.75
MEF50 (L/s) BDP--HFA 2.9071.09
BDP--CFC 2.7470.92
FEF25 (L/s) BDP--HFA 1.3270.69
BDP--CFC 1.2070.52ni¢cant di¡erences between groups were reported
except for FEF25 (P=0.044), due to a more marked in-
crease in the CFC group.
An additional equivalence analysis was also performed
for FEV1: the bilateral 95% CI was 0.05 to 0.22 l, which
lies entirely within the equivalence limit of70.30 l; this
con¢rms that BDP--HFA-134a is equivalent to BDP--
CFC.
Results of rescue daily salbutamol consumption and
clinical parameters are shown inTable 3.The asthma con-
trol tended to improve during the study in both groups
with statistically signi¢cant changes over baseline for the
majority of the parameters. There were no di¡erences
between groups for the salbutamol use or in clinical
symptoms.
No relevant changes in the mean values of morning
serumcortisolwerereportedinbothgroups: anegligible
decrease occurred in the BDP--HFA group (baseline:
15.74mg/100ml, ¢nal: 15.43mg/100ml), whereas a more
pronounced reduction was observed in the BDP--CFC
group (baseline: 17.57mg/100ml, ¢nal: 15.76mg/100ml).
However, the analysis within treatment and between
groups did not show any signi¢cant change.
The individual patients’data ofmorning serumcortisol
in the two groups (patients with both baseline and ¢nal
data) are shown in Fig. 2.Two patientswent fromnormal
to low levels inbothgroups; onepatient in the BDP--CFC
group also had a low value at baseline.The remaining pa-
tients had values within the normal range at both base-
line and end of treatment.
A total number of 64 adverse events (AEs) were re-
ported during the study, 32 in both groups, and they oc-
curred in 31% of patients in the BDP--HFA-134a and in
32% of patients in theCFC group.These included 6 ADRs
(adverse events with a de¢nite, probable, possible or
doubtful relationship with the test treatment), with 4 in
the BDP--HFA-134a group and 2 in the BDP--CFC group.
The majority of adverse events was due to seasonal dis-seline in brackets)
After 6 weeks (mean7SD) After12 weeks (mean7SD)
2.9070.68 (0.10--0.27) 2.9270.69 (0.10--0.27)
2.9470.78 (0.10--0.26) 3.0070.82 (0.16--0.37)
3.8370.94 (0.11--0.30) 3.8570.95 (0.14--0.32)
3.9671.13 (0.02--0.21) 4.0371.13 (0.09--0.32)
7.1572.01 (0.42--1.03) 7.0571.74 (0.34--1.02)
6.9671.79 (0.33--0.91) 7.1371.87 (0.54--1.16)
2.6971.08 (0.01--0.33) 2.7271.06 (0.00--0.35)
2.6370.95 (0.17--0.49) 2.6470.97 (0.15--0.51)
3.0271.15 (0.07--0.31) 3.0671.09 (0.03--0.34)
2.9871.10 (0.12--0.48) 3.0171.18 (0.11--0.51)
1.3570.69 (0.04--0.16) 1.3570.66 (0.07--0.14)
1.3970.61 (0.09--0.28) 1.3370.56 (0.10--0.31)
TABLE 3. Clinicalparameters recorded on dairycards (95% CIof changes frombaseline in brackets)
Treatment Baseline
(mean7SD)
Weeks 5--6
(mean7SD)
Weeks11--12
(mean7SD)
Salbutamol consumption (No. of pu¡s) BDP--HFA 1.6471.97 1.0171.36(0.98--0.29) 0.8871.32 (1.11--0.42)
BDP--CFC 1.2571.80 1.0071.59 (0.58--0.07) 0.9471.52 (0.68--0.03)
Daytime asthma attacks (number) BDP--HFA 0.5271.04 0.3770.76 (0.36--0.06) 0.3070.72 (0.42--0.02)
BDP--CFC 0.4470.79 0.2970.57 (0.29--0.01) 0.2870.56 (0.29--0.03)
Nighttime asthma attacks (number) BDP--HFA 0.1570.44 0.0970.26 (0.15--0.03) 0.0770.22 (0.17--0.02)
BDP--CFC 0.1770.35 0.0970.27 (0.14--0.00) 0.0570.18 (0.19--0.03)
Nighttime awakenings (number) BDP--HFA 0.1270.35 0.0470.11 (0.16--0.01) 0.0370.12 (0.17--0.03)
BDP--CFC 0.1170.24 0.0770.24 (0.09--0.02) 0.0370.11 (0.11--0.03)
Clinical symptoms (sumof scores) BDP--HFA 2.2871.90 1.3671.52 (1.31--0.53) 1.0771.28 (1.61--0.81)
BDP--CFC 2.1472.20 1.4271.50 (1.09--0.21) 1.2271.63 (1.34--0.37)
FIG. 2. Morning SerumCortisol: individualpatients’data (nor-
malrange between dotted lines: 5--25 mg/100ml)
788 RESPIRATORYMEDICINEeases: in the BDP--HFA group 7 episodes of virosis, 4
common colds, 3 upper respiratory infection and 2 rhini-
tis were reported, whereas in the BDP--CFC group the
events consistedof 8 episodes of virosis,9 commoncolds,
2 upper respiratory infection and 3 rhinitis.The adverse
reactions reported in the BDP--HFA group were 2 epi-
sodes of sore throat,1oral candidiasis and1hoarseness,
while the 2 adverse reactions reported in the BDP--CFC
group were 1 episode of common cold and 1 of sore
throat with hoarseness.Only one non-drug-related SAE
(leg injury) was reported in 1 patient in the BDP--HFA
group: this patient regularly completed the treatment.
Only 1 patient in the BDP--CFC discontinued the study
medication due to AEs.
No clinically signi¢cant changes occurred in vital signs
(heart rate and blood pressure). The compliance pro¢le
was excellent in both groups: the mean reported intake
was 99.6% in the BDP--HFA group and 99.7% in the BDP--
CFC group.DISCUSSION
The results of the present study have provided evidence
that BDP given via a new HFA-134a formulation and the
conventional CFCs are equivalent in e⁄ciency andhave a
comparable safety pro¢le in adult patients with mild-to-
moderate asthma. The two groups were equivalent in
terms of the primary e⁄cacy variable, morning PEFR,
as well as for evening PEFR and FEV1. In fact, the LSMs in
the two groups were similar and the calculated 95% CIs
for the di¡erence between treatments were well within
the 10% of the CFC group, being also contained in the
75% for morning and evening PEFR.The other
e⁄cacy parameters, consisting of pulmonary
function tests measured at clinics, clinical
symptoms (including asthma attacks and noc-
turnal awakenings) and use of rescue salbuta-
mol daily measured by patients, showed
comparable results in the two groups, without
statistically signi¢cant di¡erences between
them (apart from FEF25, P=0.044 in favour of
the HFA group).
The selection criteria of the patients’population (FEV1
between 60 and 90% of predicted normal) was planned
in order to treat subjects who had room for improve-
ment, despite a similar subset of patients in the two
groups were receiving inhaled steroids at study entry
and during run-in. In fact, according to recent reports
(9,10), treatments should be compared in the step part
of the dose--response curve, thus allowing a real di¡er-
ence, if present, to be detected.The results of this study
have shown marked and signi¢cant improvements over
baseline in the two groups in terms of lung function (i.e.
at least 20L/min in a.m. and p.m. PEFR or 0.2 l in FEV1),
symptoms and use of rescue salbutamol, thereby show-
ing that the two selected groups were adequate to
achieve better asthma control.
The safety results have shown that the two treat-
ments were equally well tolerated.Only two patients in
ANEWHFA-134a PROPELLANTRESPIRATORYMEDICINE 789each group had ¢nal serum cortisol values below the
lower limit of the normal range (one of them also had a
low baseline value).
The amount of patients with adverse events and ad-
verse drug reactions was also similar in the two groups.
Most of the adverse events were seasonal diseases af-
fecting the upper respiratory tract and only a small pro-
portion of patients in the two groups had local e¡ects
due to the intake of inhaled corticosteroids.
The Jets (Chiesi Farmaceutici S.p.A., Parma, Italy) is
a small-size spacer device aimed to retain the largest
particles of the active substance and propellant within
its internal walls; the e¡ects of the Jets spacer on
the pattern of the deposition pro¢le (11) and the advan-
tages in terms of systemic absorption when inhaled
steroids are given at high dose (12) have been previously
demonstrated. It is therefore likely that the addition of
the spacer and the use of the 1mg/day dose might have
reduced the possibility to detect any di¡erence, if it
exists, in terms of systemic tolerability. However, this
study was designed to provide equivalence on the abso-
lute e⁄cacy in an adequate sample of patients using
robust outcome measures; the results have shown that
the new HFA formulation can be used to replace the
same dose givenwith the conventional CFCwithout any
loss of e⁄cacy.
The earliest HFA-134a formulations have been devel-
oped with the aim to enhance the e⁄ciency of BDP de-
livery to the respiratory tract (14); as a consequence, the
recommended dose was reduced at approximately half
of that of conventional CFCs without altering e⁄cacy
and safety in the switching phase. In order to facilitate a
smooth transition from CFCs to alternative chlorine-
free propellants, the BDP--HFA-134a formulation used in
the present study has been developed to obtain a parti-
cle size distribution similar asmuch as possible to that of
CFCs, and thusmaintain the1:1ratio.
The results of the present study have shown that this
new formulation is therapeutically equivalent to theBDP--CFC product andmay represent a valid alternative
in the administration inhaled BDP in adult patients with
mild-to-moderate persistent asthma.
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